1	Rorer	_	NNP	_	_	2	NAME	_	_
2	Group	_	NNP	_	_	4	SBJ	_	_
3	Inc.	_	NNP	_	_	2	POSTHON	_	_
4	will	_	MD	_	_	40	OBJ	_	_
5	report	_	VB	_	_	4	VC	_	_
6	that	_	IN	_	_	5	OBJ	_	_
7	third-quarter	_	JJ	_	_	8	NMOD	_	_
8	profit	_	NN	_	_	9	SBJ	_	_
9	rose	_	VBD	_	_	6	SUB	_	_
10	more	_	RBR	_	_	12	DEP	_	_
11	than	_	IN	_	_	12	DEP	_	_
12	15	_	CD	_	_	13	NMOD	_	_
13	%	_	NN	_	_	9	EXT	_	_
14	from	_	IN	_	_	9	DIR	_	_
15	a	_	DT	_	_	16	NMOD	_	_
16	year	_	NN	_	_	17	AMOD	_	_
17	earlier	_	RBR	_	_	14	TMP	_	_
18	,	_	,	_	_	9	P	_	_
19	though	_	IN	_	_	9	ADV	_	_
20	the	_	DT	_	_	21	NMOD	_	_
21	gain	_	NN	_	_	22	SBJ	_	_
22	is	_	VBZ	_	_	19	SUB	_	_
23	wholly	_	RB	_	_	24	AMOD	_	_
24	due	_	JJ	_	_	22	PRD	_	_
25	to	_	TO	_	_	24	AMOD	_	_
26	asset	_	NN	_	_	27	NMOD	_	_
27	sales	_	NNS	_	_	25	PMOD	_	_
28	,	_	,	_	_	40	P	_	_
29	Robert	_	NNP	_	_	30	NAME	_	_
30	Cawthorn	_	NNP	_	_	40	SBJ	_	_
31	,	_	,	_	_	30	P	_	_
32	chairman	_	NN	_	_	30	APPO	_	_
33	,	_	,	_	_	32	P	_	_
34	president	_	NN	_	_	32	COORD	_	_
35	and	_	CC	_	_	34	COORD	_	_
36	chief	_	JJ	_	_	38	NMOD	_	_
37	executive	_	JJ	_	_	38	NMOD	_	_
38	officer	_	NN	_	_	35	CONJ	_	_
39	,	_	,	_	_	30	P	_	_
40	said	_	VBD	_	_	0	ROOT	_	_
41	.	_	.	_	_	40	P	_	_

1	His	_	PRP$	_	_	2	NMOD	_	_
2	projection	_	NN	_	_	3	SBJ	_	_
3	indicates	_	VBZ	_	_	0	ROOT	_	_
4	profit	_	NN	_	_	3	OBJ	_	_
5	in	_	IN	_	_	4	TMP	_	_
6	the	_	DT	_	_	8	NMOD	_	_
7	latest	_	JJS	_	_	8	NMOD	_	_
8	quarter	_	NN	_	_	5	PMOD	_	_
9	of	_	IN	_	_	4	NMOD	_	_
10	more	_	JJR	_	_	12	DEP	_	_
11	than	_	IN	_	_	12	DEP	_	_
12	$	_	$	_	_	9	PMOD	_	_
13	17.4	_	CD	_	_	12	DEP	_	_
14	million	_	CD	_	_	12	DEP	_	_
15	,	_	,	_	_	12	P	_	_
16	or	_	CC	_	_	12	COORD	_	_
17	55	_	CD	_	_	18	NMOD	_	_
18	cents	_	NNS	_	_	16	CONJ	_	_
19	a	_	DT	_	_	20	NMOD	_	_
20	share	_	NN	_	_	18	ADV	_	_
21	,	_	,	_	_	12	P	_	_
22	compared	_	VBN	_	_	12	NMOD	_	_
23	with	_	IN	_	_	22	PMOD	_	_
24	$	_	$	_	_	23	PMOD	_	_
25	15.2	_	CD	_	_	24	DEP	_	_
26	million	_	CD	_	_	24	DEP	_	_
27	,	_	,	_	_	24	P	_	_
28	or	_	CC	_	_	24	COORD	_	_
29	48	_	CD	_	_	30	NMOD	_	_
30	cents	_	NNS	_	_	28	CONJ	_	_
31	a	_	DT	_	_	32	NMOD	_	_
32	share	_	NN	_	_	30	ADV	_	_
33	,	_	,	_	_	24	P	_	_
34	a	_	DT	_	_	35	NMOD	_	_
35	year	_	NN	_	_	36	AMOD	_	_
36	ago	_	RB	_	_	24	TMP	_	_
37	.	_	.	_	_	3	P	_	_

1	Mr.	_	NNP	_	_	2	TITLE	_	_
2	Cawthorn	_	NNP	_	_	3	SBJ	_	_
3	said	_	VBD	_	_	0	ROOT	_	_
4	in	_	IN	_	_	3	LOC	_	_
5	an	_	DT	_	_	6	NMOD	_	_
6	interview	_	NN	_	_	4	PMOD	_	_
7	that	_	IN	_	_	3	OBJ	_	_
8	sales	_	NNS	_	_	9	SBJ	_	_
9	will	_	MD	_	_	7	SUB	_	_
10	show	_	VB	_	_	9	VC	_	_
11	an	_	DT	_	_	12	NMOD	_	_
12	increase	_	NN	_	_	10	OBJ	_	_
13	from	_	IN	_	_	12	NMOD	_	_
14	a	_	DT	_	_	15	NMOD	_	_
15	year	_	NN	_	_	16	AMOD	_	_
16	ago	_	RB	_	_	13	TMP	_	_
17	of	_	IN	_	_	12	NMOD	_	_
18	``	_	``	_	_	17	P	_	_
19	somewhat	_	RB	_	_	23	NMOD	_	_
20	less	_	JJR	_	_	19	DEP	_	_
21	than	_	IN	_	_	19	DEP	_	_
22	10	_	CD	_	_	19	DEP	_	_
23	%	_	NN	_	_	17	PMOD	_	_
24	.	_	.	_	_	3	P	_	_
25	''	_	''	_	_	3	P	_	_

1	Through	_	IN	_	_	10	TMP	_	_
2	the	_	DT	_	_	5	NMOD	_	_
3	first	_	JJ	_	_	5	NMOD	_	_
4	six	_	CD	_	_	5	NMOD	_	_
5	months	_	NNS	_	_	1	PMOD	_	_
6	of	_	IN	_	_	5	NMOD	_	_
7	1989	_	CD	_	_	6	PMOD	_	_
8	,	_	,	_	_	10	P	_	_
9	sales	_	NNS	_	_	10	SBJ	_	_
10	had	_	VBD	_	_	0	ROOT	_	_
11	grown	_	VBN	_	_	10	VC	_	_
12	about	_	RB	_	_	14	NMOD	_	_
13	12	_	CD	_	_	12	DEP	_	_
14	%	_	NN	_	_	11	EXT	_	_
15	from	_	IN	_	_	11	DIR	_	_
16	the	_	DT	_	_	18	NMOD	_	_
17	year-earlier	_	JJ	_	_	18	NMOD	_	_
18	period	_	NN	_	_	15	PMOD	_	_
19	.	_	.	_	_	10	P	_	_

1	Growth	_	NN	_	_	5	SBJ	_	_
2	of	_	IN	_	_	1	NMOD	_	_
3	10	_	CD	_	_	4	NMOD	_	_
4	%	_	NN	_	_	2	PMOD	_	_
5	would	_	MD	_	_	0	ROOT	_	_
6	make	_	VB	_	_	5	VC	_	_
7	sales	_	NNS	_	_	6	OBJ	_	_
8	for	_	IN	_	_	7	NMOD	_	_
9	the	_	DT	_	_	11	NMOD	_	_
10	latest	_	JJS	_	_	11	NMOD	_	_
11	quarter	_	NN	_	_	8	PMOD	_	_
12	$	_	$	_	_	6	OPRD	_	_
13	269	_	CD	_	_	12	DEP	_	_
14	million	_	CD	_	_	12	DEP	_	_
15	,	_	,	_	_	12	P	_	_
16	compared	_	VBN	_	_	12	NMOD	_	_
17	with	_	IN	_	_	16	PMOD	_	_
18	$	_	$	_	_	17	PMOD	_	_
19	244.6	_	CD	_	_	20	DEP	_	_
20	million	_	CD	_	_	18	NMOD	_	_
21	a	_	DT	_	_	22	NMOD	_	_
22	year	_	NN	_	_	23	AMOD	_	_
23	ago	_	RB	_	_	18	TMP	_	_
24	.	_	.	_	_	5	P	_	_

1	Mr.	_	NNP	_	_	2	TITLE	_	_
2	Cawthorn	_	NNP	_	_	3	SBJ	_	_
3	said	_	VBD	_	_	0	ROOT	_	_
4	the	_	DT	_	_	6	NMOD	_	_
5	profit	_	NN	_	_	6	NMOD	_	_
6	growth	_	NN	_	_	11	SBJ	_	_
7	in	_	IN	_	_	6	TMP	_	_
8	the	_	DT	_	_	10	NMOD	_	_
9	latest	_	JJS	_	_	10	NMOD	_	_
10	quarter	_	NN	_	_	7	PMOD	_	_
11	was	_	VBD	_	_	3	OBJ	_	_
12	due	_	JJ	_	_	11	PRD	_	_
13	to	_	TO	_	_	12	AMOD	_	_
14	the	_	DT	_	_	15	NMOD	_	_
15	sale	_	NN	_	_	13	PMOD	_	_
16	of	_	IN	_	_	15	NMOD	_	_
17	two	_	CD	_	_	19	NMOD	_	_
18	Rorer	_	NNP	_	_	19	NMOD	_	_
19	drugs	_	NNS	_	_	16	PMOD	_	_
20	.	_	.	_	_	3	P	_	_

1	Asilone	_	NNP	_	_	6	SBJ	_	_
2	,	_	,	_	_	1	P	_	_
3	an	_	DT	_	_	4	NMOD	_	_
4	antacid	_	NN	_	_	1	APPO	_	_
5	,	_	,	_	_	1	P	_	_
6	was	_	VBD	_	_	0	ROOT	_	_
7	sold	_	VBN	_	_	6	VC	_	_
8	to	_	TO	_	_	7	DTV	_	_
9	Boots	_	NNP	_	_	10	NAME	_	_
10	PLC	_	NNP	_	_	8	PMOD	_	_
11	,	_	,	_	_	10	P	_	_
12	London	_	NNP	_	_	10	LOC	_	_
13	.	_	.	_	_	6	P	_	_

1	Thrombinar	_	NNP	_	_	10	SBJ	_	_
2	,	_	,	_	_	1	P	_	_
3	a	_	DT	_	_	4	NMOD	_	_
4	drug	_	NN	_	_	1	APPO	_	_
5	used	_	VBN	_	_	4	APPO	_	_
6	to	_	TO	_	_	5	OPRD	_	_
7	stanch	_	VB	_	_	6	IM	_	_
8	bleeding	_	NN	_	_	7	OBJ	_	_
9	,	_	,	_	_	1	P	_	_
10	was	_	VBD	_	_	0	ROOT	_	_
11	sold	_	VBN	_	_	10	VC	_	_
12	to	_	TO	_	_	11	DTV	_	_
13	Jones	_	NNP	_	_	15	NAME	_	_
14	Medical	_	NNP	_	_	15	NAME	_	_
15	Industries	_	NNP	_	_	12	PMOD	_	_
16	Inc.	_	NNP	_	_	15	POSTHON	_	_
17	,	_	,	_	_	15	P	_	_
18	St.	_	NNP	_	_	19	TITLE	_	_
19	Louis	_	NNP	_	_	15	LOC	_	_
20	.	_	.	_	_	10	P	_	_

1	He	_	PRP	_	_	2	SBJ	_	_
2	said	_	VBD	_	_	0	ROOT	_	_
3	Rorer	_	NNP	_	_	4	SBJ	_	_
4	sold	_	VBD	_	_	2	OBJ	_	_
5	the	_	DT	_	_	6	NMOD	_	_
6	drugs	_	NNS	_	_	4	OBJ	_	_
7	for	_	IN	_	_	4	ADV	_	_
8	``	_	``	_	_	7	P	_	_
9	nice	_	JJ	_	_	10	NMOD	_	_
10	prices	_	NNS	_	_	7	PMOD	_	_
11	''	_	''	_	_	7	P	_	_
12	and	_	CC	_	_	4	COORD	_	_
13	will	_	MD	_	_	12	CONJ	_	_
14	record	_	VB	_	_	13	VC	_	_
15	a	_	DT	_	_	19	NMOD	_	_
16	combined	_	VBN	_	_	19	NMOD	_	_
17	,	_	,	_	_	19	P	_	_
18	pretax	_	JJ	_	_	19	NMOD	_	_
19	gain	_	NN	_	_	14	OBJ	_	_
20	on	_	IN	_	_	19	LOC	_	_
21	the	_	DT	_	_	22	NMOD	_	_
22	sales	_	NNS	_	_	20	PMOD	_	_
23	of	_	IN	_	_	19	NMOD	_	_
24	$	_	$	_	_	23	PMOD	_	_
25	20	_	CD	_	_	24	DEP	_	_
26	million	_	CD	_	_	24	DEP	_	_
27	.	_	.	_	_	2	P	_	_

1	As	_	IN	_	_	11	ADV	_	_
2	the	_	DT	_	_	3	NMOD	_	_
3	gain	_	NN	_	_	7	SBJ	_	_
4	from	_	IN	_	_	3	NMOD	_	_
5	the	_	DT	_	_	6	NMOD	_	_
6	sales	_	NNS	_	_	4	PMOD	_	_
7	indicates	_	VBZ	_	_	1	SUB	_	_
8	,	_	,	_	_	11	P	_	_
9	operating	_	NN	_	_	10	NMOD	_	_
10	profit	_	NN	_	_	11	SBJ	_	_
11	was	_	VBD	_	_	22	OBJ	_	_
12	``	_	``	_	_	15	P	_	_
13	significantly	_	RB	_	_	15	PMOD	_	_
14	''	_	''	_	_	15	P	_	_
15	below	_	IN	_	_	11	LOC-PRD	_	_
16	the	_	DT	_	_	18	NMOD	_	_
17	year-earlier	_	JJ	_	_	18	NMOD	_	_
18	level	_	NN	_	_	15	PMOD	_	_
19	,	_	,	_	_	22	P	_	_
20	Mr.	_	NNP	_	_	21	TITLE	_	_
21	Cawthorn	_	NNP	_	_	22	SBJ	_	_
22	said	_	VBD	_	_	0	ROOT	_	_
23	.	_	.	_	_	22	P	_	_

1	Rorer	_	NNP	_	_	4	SBJ	_	_
2	in	_	IN	_	_	4	TMP	_	_
3	July	_	NNP	_	_	2	PMOD	_	_
4	had	_	VBD	_	_	0	ROOT	_	_
5	projected	_	VBN	_	_	4	VC	_	_
6	lower	_	JJR	_	_	9	NMOD	_	_
7	third-quarter	_	JJ	_	_	9	NMOD	_	_
8	operating	_	NN	_	_	9	NMOD	_	_
9	profit	_	NN	_	_	5	OBJ	_	_
10	but	_	CC	_	_	9	COORD	_	_
11	higher	_	JJR	_	_	12	NMOD	_	_
12	profit	_	NN	_	_	10	CONJ	_	_
13	for	_	IN	_	_	12	NMOD	_	_
14	all	_	DT	_	_	13	PMOD	_	_
15	of	_	IN	_	_	14	NMOD	_	_
16	1989	_	CD	_	_	15	PMOD	_	_
17	.	_	.	_	_	4	P	_	_

1	He	_	PRP	_	_	2	SBJ	_	_
2	said	_	VBD	_	_	0	ROOT	_	_
3	the	_	DT	_	_	4	NMOD	_	_
4	company	_	NN	_	_	5	SBJ	_	_
5	is	_	VBZ	_	_	2	OBJ	_	_
6	still	_	RB	_	_	5	TMP	_	_
7	looking	_	VBG	_	_	5	VC	_	_
8	for	_	IN	_	_	7	ADV	_	_
9	``	_	``	_	_	8	P	_	_
10	a	_	DT	_	_	13	NMOD	_	_
11	strong	_	JJ	_	_	13	NMOD	_	_
12	fourth	_	JJ	_	_	13	NMOD	_	_
13	quarter	_	NN	_	_	8	PMOD	_	_
14	in	_	IN	_	_	13	LOC	_	_
15	all	_	DT	_	_	16	NMOD	_	_
16	areas	_	NNS	_	_	14	PMOD	_	_
17	--	_	:	_	_	16	P	_	_
18	sales	_	NNS	_	_	16	APPO	_	_
19	,	_	,	_	_	18	P	_	_
20	operating	_	NN	_	_	21	NMOD	_	_
21	income	_	NN	_	_	18	COORD	_	_
22	and	_	CC	_	_	21	COORD	_	_
23	net	_	JJ	_	_	24	NMOD	_	_
24	income	_	NN	_	_	22	CONJ	_	_
25	.	_	.	_	_	2	P	_	_
26	''	_	''	_	_	2	P	_	_

1	Mr.	_	NNP	_	_	2	TITLE	_	_
2	Cawthorn	_	NNP	_	_	3	SBJ	_	_
3	attributed	_	VBD	_	_	0	ROOT	_	_
4	the	_	DT	_	_	5	NMOD	_	_
5	decline	_	NN	_	_	3	OBJ	_	_
6	in	_	IN	_	_	5	LOC	_	_
7	third-quarter	_	JJ	_	_	9	NMOD	_	_
8	operating	_	NN	_	_	9	NMOD	_	_
9	profit	_	NN	_	_	6	PMOD	_	_
10	to	_	TO	_	_	3	ADV	_	_
11	the	_	DT	_	_	13	NMOD	_	_
12	stronger	_	JJR	_	_	13	NMOD	_	_
13	dollar	_	NN	_	_	10	PMOD	_	_
14	,	_	,	_	_	13	P	_	_
15	which	_	WDT	_	_	16	SBJ	_	_
16	reduces	_	VBZ	_	_	13	NMOD	_	_
17	the	_	DT	_	_	18	NMOD	_	_
18	value	_	NN	_	_	16	OBJ	_	_
19	of	_	IN	_	_	18	NMOD	_	_
20	overseas	_	JJ	_	_	21	NMOD	_	_
21	profit	_	NN	_	_	19	PMOD	_	_
22	when	_	WRB	_	_	25	TMP	_	_
23	it	_	PRP	_	_	24	SBJ	_	_
24	is	_	VBZ	_	_	18	NMOD	_	_
25	translated	_	VBN	_	_	24	VC	_	_
26	into	_	IN	_	_	25	ADV	_	_
27	dollars	_	NNS	_	_	26	PMOD	_	_
28	;	_	:	_	_	10	P	_	_
29	to	_	TO	_	_	10	COORD	_	_
30	accelerated	_	VBN	_	_	31	NMOD	_	_
31	buying	_	NN	_	_	29	PMOD	_	_
32	of	_	IN	_	_	31	NMOD	_	_
33	Rorer	_	NNP	_	_	34	NMOD	_	_
34	products	_	NNS	_	_	32	PMOD	_	_
35	in	_	IN	_	_	31	TMP	_	_
36	the	_	DT	_	_	38	NMOD	_	_
37	second	_	JJ	_	_	38	NMOD	_	_
38	quarter	_	NN	_	_	35	PMOD	_	_
39	because	_	IN	_	_	31	PRP	_	_
40	of	_	IN	_	_	39	DEP	_	_
41	a	_	DT	_	_	46	NMOD	_	_
42	then-pending	_	JJ	_	_	46	NMOD	_	_
43	July	_	NNP	_	_	46	TMP	_	_
44	1	_	CD	_	_	43	NMOD	_	_
45	price	_	NN	_	_	46	NMOD	_	_
46	increase	_	NN	_	_	39	PMOD	_	_
47	,	_	,	_	_	29	P	_	_
48	and	_	CC	_	_	29	COORD	_	_
49	to	_	TO	_	_	48	CONJ	_	_
50	higher	_	JJR	_	_	52	NMOD	_	_
51	marketing	_	NN	_	_	52	NMOD	_	_
52	expenses	_	NNS	_	_	49	PMOD	_	_
53	for	_	IN	_	_	52	NMOD	_	_
54	Rorer	_	NNP	_	_	57	NMOD	_	_
55	's	_	POS	_	_	54	SUFFIX	_	_
56	Maalox	_	NNP	_	_	57	NMOD	_	_
57	antacid	_	NN	_	_	53	PMOD	_	_
58	,	_	,	_	_	57	P	_	_
59	whose	_	WP$	_	_	60	NMOD	_	_
60	sales	_	NNS	_	_	67	SBJ	_	_
61	and	_	CC	_	_	60	COORD	_	_
62	market	_	NN	_	_	61	CONJ	_	_
63	share	_	NN	_	_	62	COORD	_	_
64	in	_	IN	_	_	60	LOC	_	_
65	the	_	DT	_	_	66	NMOD	_	_
66	U.S.	_	NNP	_	_	64	PMOD	_	_
67	had	_	VBD	_	_	57	NMOD	_	_
68	slipped	_	VBN	_	_	67	VC	_	_
69	in	_	IN	_	_	68	TMP	_	_
70	the	_	DT	_	_	72	NMOD	_	_
71	first	_	JJ	_	_	72	NMOD	_	_
72	half	_	NN	_	_	69	PMOD	_	_
73	of	_	IN	_	_	72	NMOD	_	_
74	1989	_	CD	_	_	73	PMOD	_	_
75	.	_	.	_	_	3	P	_	_

1	He	_	PRP	_	_	2	SBJ	_	_
2	said	_	VBD	_	_	0	ROOT	_	_
3	Rorer	_	NNP	_	_	4	SBJ	_	_
4	opted	_	VBD	_	_	2	OBJ	_	_
5	to	_	TO	_	_	4	OPRD	_	_
6	sell	_	VB	_	_	5	IM	_	_
7	Asilone	_	NNP	_	_	6	OBJ	_	_
8	and	_	CC	_	_	7	COORD	_	_
9	Thrombinar	_	NNP	_	_	8	CONJ	_	_
10	to	_	TO	_	_	6	PRP	_	_
11	raise	_	VB	_	_	10	IM	_	_
12	revenue	_	NN	_	_	11	OBJ	_	_
13	that	_	WDT	_	_	14	SBJ	_	_
14	would	_	MD	_	_	12	NMOD	_	_
15	``	_	``	_	_	17	P	_	_
16	kick	_	NN	_	_	17	DEP	_	_
17	start	_	VB	_	_	14	VC	_	_
18	''	_	''	_	_	17	P	_	_
19	its	_	PRP$	_	_	22	NMOD	_	_
20	increased	_	VBN	_	_	22	NMOD	_	_
21	marketing	_	NN	_	_	22	NMOD	_	_
22	efforts	_	NNS	_	_	17	OBJ	_	_
23	behind	_	IN	_	_	22	LOC	_	_
24	Maalox	_	NNP	_	_	23	PMOD	_	_
25	,	_	,	_	_	24	P	_	_
26	still	_	RB	_	_	24	TMP	_	_
27	its	_	PRP$	_	_	29	NMOD	_	_
28	top-selling	_	JJ	_	_	29	NMOD	_	_
29	product	_	NN	_	_	24	APPO	_	_
30	with	_	IN	_	_	24	NMOD	_	_
31	about	_	RB	_	_	32	DEP	_	_
32	$	_	$	_	_	30	PMOD	_	_
33	215	_	CD	_	_	32	DEP	_	_
34	million	_	CD	_	_	32	DEP	_	_
35	in	_	IN	_	_	32	LOC	_	_
36	world-wide	_	JJ	_	_	37	NMOD	_	_
37	sales	_	NNS	_	_	35	PMOD	_	_
38	in	_	IN	_	_	32	TMP	_	_
39	1988	_	CD	_	_	38	PMOD	_	_
40	.	_	.	_	_	2	P	_	_

1	``	_	``	_	_	3	P	_	_
2	We	_	PRP	_	_	3	SBJ	_	_
3	had	_	VBD	_	_	12	OBJ	_	_
4	underfunded	_	VBN	_	_	3	VC	_	_
5	Maalox	_	NNP	_	_	4	OBJ	_	_
6	for	_	IN	_	_	4	TMP	_	_
7	a	_	DT	_	_	8	NMOD	_	_
8	year	_	NN	_	_	6	PMOD	_	_
9	,	_	,	_	_	12	P	_	_
10	''	_	''	_	_	12	P	_	_
11	he	_	PRP	_	_	12	SBJ	_	_
12	said	_	VBD	_	_	0	ROOT	_	_
13	,	_	,	_	_	12	P	_	_
14	because	_	IN	_	_	4	PRP	_	_
15	the	_	DT	_	_	16	NMOD	_	_
16	company	_	NN	_	_	17	SBJ	_	_
17	was	_	VBD	_	_	14	SUB	_	_
18	concentrating	_	VBG	_	_	17	VC	_	_
19	on	_	IN	_	_	18	ADV	_	_
20	research	_	NN	_	_	19	PMOD	_	_
21	and	_	CC	_	_	20	COORD	_	_
22	development	_	NN	_	_	21	CONJ	_	_
23	and	_	CC	_	_	22	COORD	_	_
24	promoting	_	VBG	_	_	23	CONJ	_	_
25	other	_	JJ	_	_	26	NMOD	_	_
26	drugs	_	NNS	_	_	24	OBJ	_	_
27	.	_	.	_	_	3	P	_	_

1	He	_	PRP	_	_	2	SBJ	_	_
2	said	_	VBD	_	_	0	ROOT	_	_
3	Rorer	_	NNP	_	_	4	SBJ	_	_
4	will	_	MD	_	_	2	OBJ	_	_
5	spend	_	VB	_	_	4	VC	_	_
6	$	_	$	_	_	13	NMOD	_	_
7	15	_	CD	_	_	6	DEP	_	_
8	million	_	CD	_	_	6	DEP	_	_
9	to	_	TO	_	_	6	DEP	_	_
10	$	_	$	_	_	6	DEP	_	_
11	20	_	CD	_	_	6	DEP	_	_
12	million	_	CD	_	_	6	DEP	_	_
13	more	_	JJR	_	_	5	OBJ	_	_
14	on	_	IN	_	_	5	ADV	_	_
15	Maalox	_	NNP	_	_	16	NMOD	_	_
16	advertising	_	NN	_	_	14	PMOD	_	_
17	and	_	CC	_	_	16	COORD	_	_
18	promotion	_	NN	_	_	17	CONJ	_	_
19	in	_	IN	_	_	16	TMP	_	_
20	the	_	DT	_	_	22	NMOD	_	_
21	second	_	JJ	_	_	22	NMOD	_	_
22	half	_	NN	_	_	19	PMOD	_	_
23	of	_	IN	_	_	22	NMOD	_	_
24	1989	_	CD	_	_	23	PMOD	_	_
25	than	_	IN	_	_	13	NMOD	_	_
26	in	_	IN	_	_	25	TMP	_	_
27	the	_	DT	_	_	29	NMOD	_	_
28	year-earlier	_	JJ	_	_	29	NMOD	_	_
29	period	_	NN	_	_	26	PMOD	_	_
30	.	_	.	_	_	2	P	_	_

1	A	_	DT	_	_	4	NMOD	_	_
2	``	_	``	_	_	4	P	_	_
3	big	_	JJ	_	_	4	NMOD	_	_
4	chunk	_	NN	_	_	10	SBJ	_	_
5	''	_	''	_	_	4	P	_	_
6	of	_	IN	_	_	4	NMOD	_	_
7	that	_	DT	_	_	9	NMOD	_	_
8	additional	_	JJ	_	_	9	NMOD	_	_
9	spending	_	NN	_	_	6	PMOD	_	_
10	came	_	VBD	_	_	17	OBJ	_	_
11	in	_	IN	_	_	10	TMP	_	_
12	the	_	DT	_	_	14	NMOD	_	_
13	third	_	JJ	_	_	14	NMOD	_	_
14	quarter	_	NN	_	_	11	PMOD	_	_
15	,	_	,	_	_	17	P	_	_
16	he	_	PRP	_	_	17	SBJ	_	_
17	said	_	VBD	_	_	0	ROOT	_	_
18	.	_	.	_	_	17	P	_	_

